Edition:
United States

Sosei Group Corp (4565.T)

4565.T on Tokyo Stock Exchange

9,850JPY
18 Oct 2017
Change (% chg)

¥20 (+0.20%)
Prev Close
¥9,830
Open
¥9,870
Day's High
¥9,920
Day's Low
¥9,780
Volume
175,600
Avg. Vol
422,543
52-wk High
¥17,400
52-wk Low
¥8,590

Chart for

About

Sosei Group Corporation is a holding company primarily engaged in the biopharmaceutical business. The Company is mainly involved in the research, development and sale of pharmaceutical drugs, including NVA237 and QVA149, used for chronic obstructive pulmonary disease; SO - 1105, used for oral thrush. As of March 31, 2013, the... (more)

Overall

Beta: 1.53
Market Cap(Mil.): ¥166,853.30
Shares Outstanding(Mil.): 16.97
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.63 16.86
EPS (TTM): -- -- --
ROI: -- 14.92 11.22
ROE: -- 16.17 15.09

BRIEF-Sosei Group unit says first subject dosed in Phase1 clinical study of novel selective muscarinic M4 agonist in development to treat major symptoms of Alzheimer's disease

* Says co's unit Heptares Therapeutics and Allergan announced that the first healthy subject has been dosed with the first-in-class, selective muscarinic M4 receptor agonist HTL0016878 in a Phase 1 clinical study

Aug 31 2017

BRIEF-Sosei Group to sell Chiba-based pharmaceutical unit for $3.5 mln

* Says it will sell Chiba-based pharmaceutical unit to Formosa Pharmaceuticals, Inc., which is unit of Formosa Laboratories, Inc, for $3.5 million

Aug 04 2017

BRIEF- Sosei Group subsidiary Heptares enters strategic collaboration with PeptiDream

* Says its unit Heptares Therapeutics and PeptiDream Inc , a public Tokyo-based biopharmaceutical company, have entered into a strategic collaboration to discover, develop and commercialise novel therapeutics targeting an undisclosed G protein-coupled receptor (GPCR) with an important role in inflammatory diseases

Jun 29 2017

BRIEF- Sosei Group unit Heptares to receive $5 million milestone

* Says a preclinical candidate calcitonin gene-related eptide (CGRP) antagonist, discovered by Heptares using its structure-based design approach in partnership with Teva Pharmaceutical Industries Ltd has triggered a $5 million payment from Teva to Heptares under the terms of their licensing and drug-discovery agreement signed in 2015

May 18 2017

BRIEF-Sosei Group unit signs investment agreement with MiNA

* Says co's wholly owned subsidiary Sosei R&D Limited signs an investment agreement with MiNA (Holdings) Limited, which is the holding company of UK-based bio-medical firm MiNA Therapeutics Limited

May 02 2017

Earnings vs. Estimates